Skip to content
DataLookout
Menu

BRIGHTNCT07945340

Effect of a Nicotinamide Riboside-Based Dietary Supplement on Retinal Function in Glaucoma (BRIGHT)

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change in PhNR Peak-to-Trough Amplitude (PhNRPT)
Timeframe: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)

Secondary (14)

Change in ERG b-Wave Amplitude
Change in ERG b-Wave Implicit Time
Change in Photopic Electroretinogram (ERG) W-Ratio
Change in Circumpapillary Retinal Nerve Fiber Layer (RNFL) Thickness and Ganglion Cell Complex (GCC) Thickness
Change in Best-Corrected Visual Acuity (BCVA)
Show 9 moreShow less
Change in Intraocular Pressure (IOP)
Change in Mean Arterial Pressure (MAP)
Proportion of Participants With a Change of at Least 1 dB in Visual Field Mean Deviation and Pattern Standard Deviation
Change in 24-2 Visual Field Mean Deviation (MD)
Change in 24-2 Visual Field Pattern Standard Deviation (PSD)
Change in 24-2 Visual Field Mean Light Sensitivity (MLS)
Change in 10-2 Visual Field Mean Deviation (MD)
Change in 10-2 Visual Field Pattern Standard Deviation (PSD)
Change in 10-2 Visual Field Mean Light Sensitivity (MLS)

Arms and interventions

Sequence A: iNAD CONTROL then PlaceboExperimental

Participants take iNAD CONTROL, 1 tablet orally once daily, for 12 weeks (Period 1), then cross over at Week 12 without a wash-out period to matching placebo, 1 tablet orally once daily, for 12 weeks (Period 2). Usual IOP-lowering glaucoma therapy continues unchanged throughout.

Sequence B: Placebo then iNAD CONTROLExperimental

Participants take matching placebo, 1 tablet orally once daily, for 12 weeks (Period 1), then cross over at Week 12 without a wash-out period to iNAD CONTROL, 1 tablet orally once daily, for 12 weeks (Period 2). Usual IOP-lowering glaucoma therapy continues unchanged throughout.

Dietary supplements: iNAD CONTROL, Placebo